The content is available as a PDF (1.4 MB).
. 2022 Jun 16;162(7):S-677–S-678. doi: 10.1016/S0016-5085(22)61588-9
Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
Deborah Baik
, Raja Atreya
, Yoram Bouhnik
, Daniel Casey
, Minyoung Jang
, SangWook Yoon
, Taek S Kwon
Deborah Baik
Find articles by Deborah Baik
Raja Atreya
Find articles by Raja Atreya
Yoram Bouhnik
Find articles by Yoram Bouhnik
Daniel Casey
Find articles by Daniel Casey
Minyoung Jang
Find articles by Minyoung Jang
SangWook Yoon
Find articles by SangWook Yoon
Taek S Kwon
Find articles by Taek S Kwon
Issue date 2022 May.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC9212299